TxCell has established a proprietary T cell technology platform, based on type 1 regulatory T cells (Tr1 cells) (link).

Tr1 cells have been shown to have a strong therapeutic benefit in several animal models representative of severe chronic inflammatory diseases like Crohn's disease, rheumatoid arthritis, multiple sclerosis and others.

Tr1 cells are naturally occurring regulatory T lymphocytes, which are obtained from patient blood sample and after ex-vivo expansion and re-education with antigen stimulation, are re-infused into the patient.
These cells migrate preferentially to the site of injury and specifically inhibit the underlying inflammatory disease process (link).

To date, TxCell has a broad patent portfolio covering the phenotype and mechanism of action, as well as the manufacturing process and therapeutic use of Tr1 cells in severe chronic inflammatory diseases (link).

We have completed a dose escalation Phase I/II study in severe, treatment resistant Crohn's disease patients, to evaluate the safety and preliminary efficacy of the technology platform (link).

Our goal is to establish the safety and efficacy of this novel and promising therapeutic modality for the treatment of severe, chronic inflammatory diseases with a high unmet medical need.